HK1084015A1 - Stable pharmaceutical compositions of 2-aza-bicyclo3.3.0 -octane-3- carboxylic acid derivatives 2- - Google Patents
Stable pharmaceutical compositions of 2-aza-bicyclo3.3.0 -octane-3- carboxylic acid derivatives 2-Info
- Publication number
- HK1084015A1 HK1084015A1 HK06103919.6A HK06103919A HK1084015A1 HK 1084015 A1 HK1084015 A1 HK 1084015A1 HK 06103919 A HK06103919 A HK 06103919A HK 1084015 A1 HK1084015 A1 HK 1084015A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- aza
- octane
- carboxylic acid
- pharmaceutical compositions
- acid derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A stable composition of a 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivative and a method for its preparation are described. The stable composition includes an intimate admixture of the derivative and a stabilizing effective amount of a lubricant. The stable composition further includes an external excipient. A method of preparing the stable composition includes forming an intimate admixture of the derivative and a lubricant and then blending the intimate admixture with at least one excipient. Preferably the final blend is transformed into solid unit dosage form.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48251803P | 2003-06-26 | 2003-06-26 | |
PCT/US2004/020484 WO2005002548A1 (en) | 2003-06-26 | 2004-06-24 | Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1084015A1 true HK1084015A1 (en) | 2006-07-21 |
Family
ID=33563864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06103919.6A HK1084015A1 (en) | 2003-06-26 | 2006-03-29 | Stable pharmaceutical compositions of 2-aza-bicyclo3.3.0 -octane-3- carboxylic acid derivatives 2- |
Country Status (13)
Country | Link |
---|---|
US (3) | US20050069586A1 (en) |
EP (1) | EP1635792B1 (en) |
AT (1) | ATE424192T1 (en) |
CA (1) | CA2530788C (en) |
DE (1) | DE602004019777D1 (en) |
DK (1) | DK1635792T3 (en) |
ES (1) | ES2322854T3 (en) |
HK (1) | HK1084015A1 (en) |
IL (1) | IL172602A0 (en) |
MX (1) | MXPA06000226A (en) |
PL (1) | PL1635792T3 (en) |
PT (1) | PT1635792E (en) |
WO (1) | WO2005002548A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2530788C (en) * | 2003-06-26 | 2010-02-09 | Teva Pharmaceutical Industries Ltd | Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives |
US20050095287A1 (en) * | 2003-10-29 | 2005-05-05 | Matharu Amol S. | Fosinopril composition |
WO2005067887A2 (en) * | 2004-03-24 | 2005-07-28 | Actavis Group | Formulations of ramipril |
HUE031058T2 (en) * | 2004-03-29 | 2017-06-28 | Servier Lab | Process for preparing a solid pharmaceutical composition |
ZA200704767B (en) * | 2004-11-05 | 2008-08-27 | King Pharmaceuticals Res & Dev | Stabilized individually coated ramipril particles, compositions and methods |
GB0518129D0 (en) * | 2005-09-06 | 2005-10-12 | Arrow Int Ltd | Ramipril formulation |
GB2431579A (en) * | 2005-10-28 | 2007-05-02 | Arrow Int Ltd | Ramipril formulations |
US20070098782A1 (en) * | 2005-10-28 | 2007-05-03 | Selamine Limited | Ramipril Formulation |
JP2009533461A (en) * | 2006-04-19 | 2009-09-17 | テバ ファーマシューティカル インダストリーズ リミティド | Stable pharmaceutical composition of 2-aza-bicyclo [3.3.0] -octane-3-carboxylic acid derivative |
GB0624090D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amine salts |
GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
GB0624084D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
WO2008132756A1 (en) * | 2007-05-01 | 2008-11-06 | Lupin Limited | Stable pharmaceutical compositions of ramipril |
TR200906322A2 (en) | 2009-08-17 | 2011-07-21 | Bi̇lgi̇ç Mahmut | Granules with improved solubility and stability properties. |
US9186333B2 (en) * | 2011-08-01 | 2015-11-17 | Teva Pharmaceutical Industries Ltd. | Process for preparing pharmaceutical compositions of fingolimod |
EA030466B1 (en) | 2012-02-17 | 2018-08-31 | Эгиш Дьёдьсердьяр Зрт. | Pharmaceutical formulation having improved stability |
HUP1300496A2 (en) | 2013-08-16 | 2015-03-02 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Stable pharmaceutical composition |
EP3275432A1 (en) * | 2016-07-25 | 2018-01-31 | H e x a l Aktiengesellschaft | Dosage form with ace inhibitor |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2812314A (en) * | 1952-08-23 | 1957-11-05 | Monsanto Chemicals | Calcium and alkali metal double salts of hydrolyzed polyacrylonitrile |
US2812344A (en) * | 1956-02-13 | 1957-11-05 | Ortho Pharma Corp | Ferrous calcium citrate complex |
ZA817261B (en) * | 1980-10-23 | 1982-09-29 | Schering Corp | Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them |
DE3226768A1 (en) * | 1981-11-05 | 1983-05-26 | Hoechst Ag, 6230 Frankfurt | DERIVATIVES OF CIS, ENDO-2-AZABICYCLO- (3.3.0) -OCTAN-3-CARBONIC ACID, METHOD FOR THE PRODUCTION THEREOF, THE MEANS CONTAINING THEM AND THE USE THEREOF |
US4793998A (en) * | 1986-10-20 | 1988-12-27 | Warner-Lambert Company | Stabilized drug compositions |
US4830853A (en) * | 1986-10-20 | 1989-05-16 | Warner-Lambert Company | Drug compositions stabilized against oxidation |
US4743450A (en) * | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Stabilized compositions |
DE3739690A1 (en) * | 1987-11-24 | 1989-06-08 | Hoechst Ag | STABILIZED MEDICINAL PRODUCTS, METHOD FOR THEIR PRODUCTION AND STABLE MEDICAL PREPARATIONS |
US5054483A (en) * | 1989-03-06 | 1991-10-08 | Hood Laboratories | Tracheal cannulas and stents |
US4973470A (en) * | 1989-06-26 | 1990-11-27 | Warner-Lambert Company | Sustained release pharmaceutical compositions |
US5006344A (en) * | 1989-07-10 | 1991-04-09 | E. R. Squibb & Sons, Inc. | Fosinopril tablet formulations |
DK9200258U4 (en) * | 1992-03-11 | 1993-07-23 | Merck & Co Inc | Pharmaceutical preparation containing enalapril for use in hypertension |
TW483763B (en) * | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
BR9910947A (en) * | 1998-06-05 | 2001-03-06 | Warner Lambert Co | Stabilization of compositions containing ace inhibitors using magnesium oxide |
US6555551B1 (en) * | 1999-08-31 | 2003-04-29 | Mutual Pharmaceutical Co., Inc. | Stable formulations of ACE inhibitors, and methods for preparation thereof |
US6979462B1 (en) * | 2000-10-03 | 2005-12-27 | Mutual Pharmaceutical Co., Inc. | Stabilization of solid drug formulations |
CA2330904C (en) * | 2001-01-11 | 2006-10-24 | Bernard Charles Sherman | Fosinopril sodium tablet formulation |
US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
IS1935B (en) * | 2002-03-19 | 2004-06-16 | Actavis Group Hf. | Fosinopril pharmaceutical composition |
US20040137054A1 (en) * | 2002-05-03 | 2004-07-15 | Alexandra Hager | Stable pharmaceutical formulation for a combination of a statin and an ace-inhibitors |
TW200306799A (en) * | 2002-05-17 | 2003-12-01 | Novartis Ag | Combination of organic compounds |
AR039744A1 (en) * | 2002-06-26 | 2005-03-09 | Alza Corp | METHODS AND DOSAGE FORMS TO INCREASE THE SOLUBILITY OF PHARMACOS COMPOSITIONS FOR CONTROLLED ADMINISTRATION |
CA2530788C (en) * | 2003-06-26 | 2010-02-09 | Teva Pharmaceutical Industries Ltd | Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives |
US6869963B2 (en) * | 2003-07-11 | 2005-03-22 | Sandoz Ag | Stable pharmaceutical compositions containing an ACE inhibitor |
US20050181055A1 (en) * | 2003-10-08 | 2005-08-18 | Mathur Rajeev S. | Pharmaceutical compositions of quinapril |
US20050095287A1 (en) * | 2003-10-29 | 2005-05-05 | Matharu Amol S. | Fosinopril composition |
US20050256056A1 (en) * | 2003-12-05 | 2005-11-17 | The Regents Of The University Of California Office Of Technology Transfer University Of California | Peptide inhibitors of HIV |
US20060045911A1 (en) * | 2004-08-27 | 2006-03-02 | Sun Pharmaceutical Industries Ltd. | Stable pharmaceutical formulations |
ZA200704767B (en) * | 2004-11-05 | 2008-08-27 | King Pharmaceuticals Res & Dev | Stabilized individually coated ramipril particles, compositions and methods |
US20070009591A1 (en) * | 2005-07-07 | 2007-01-11 | Trivedi Jay S | ACE inhibitor formulation |
GB2431579A (en) * | 2005-10-28 | 2007-05-02 | Arrow Int Ltd | Ramipril formulations |
US20070116762A1 (en) * | 2005-11-07 | 2007-05-24 | Wilson Edward S | Compositions of stabilized ramipril in combination with another active agent |
-
2004
- 2004-06-24 CA CA2530788A patent/CA2530788C/en not_active Expired - Fee Related
- 2004-06-24 PL PL04756130T patent/PL1635792T3/en unknown
- 2004-06-24 DK DK04756130T patent/DK1635792T3/en active
- 2004-06-24 AT AT04756130T patent/ATE424192T1/en not_active IP Right Cessation
- 2004-06-24 ES ES04756130T patent/ES2322854T3/en active Active
- 2004-06-24 WO PCT/US2004/020484 patent/WO2005002548A1/en active Application Filing
- 2004-06-24 PT PT04756130T patent/PT1635792E/en unknown
- 2004-06-24 EP EP04756130A patent/EP1635792B1/en active Active
- 2004-06-24 MX MXPA06000226A patent/MXPA06000226A/en active IP Right Grant
- 2004-06-24 US US10/877,027 patent/US20050069586A1/en not_active Abandoned
- 2004-06-24 DE DE602004019777T patent/DE602004019777D1/en active Active
-
2005
- 2005-12-15 IL IL172602A patent/IL172602A0/en not_active IP Right Cessation
-
2006
- 2006-03-29 HK HK06103919.6A patent/HK1084015A1/en not_active IP Right Cessation
-
2007
- 2007-05-10 US US11/801,777 patent/US20070212409A1/en not_active Abandoned
- 2007-10-26 US US11/977,860 patent/US20080058404A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1635792A1 (en) | 2006-03-22 |
DE602004019777D1 (en) | 2009-04-16 |
MXPA06000226A (en) | 2006-03-21 |
DK1635792T3 (en) | 2009-06-15 |
US20070212409A1 (en) | 2007-09-13 |
PT1635792E (en) | 2009-05-15 |
EP1635792B1 (en) | 2009-03-04 |
ATE424192T1 (en) | 2009-03-15 |
CA2530788C (en) | 2010-02-09 |
CA2530788A1 (en) | 2005-01-13 |
ES2322854T3 (en) | 2009-06-30 |
US20050069586A1 (en) | 2005-03-31 |
WO2005002548A1 (en) | 2005-01-13 |
PL1635792T3 (en) | 2009-08-31 |
IL172602A0 (en) | 2006-04-10 |
US20080058404A1 (en) | 2008-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1084015A1 (en) | Stable pharmaceutical compositions of 2-aza-bicyclo3.3.0 -octane-3- carboxylic acid derivatives 2- | |
WO2001085257A3 (en) | Opioid antagonist compositions and dosage forms | |
ZA200005915B (en) | Pharmaceutical compositions capable of being gelled. | |
AU3435497A (en) | Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies | |
MY144992A (en) | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives. | |
PL1750862T3 (en) | Pharmaceutical composition containing irbesartan | |
TR200100894T2 (en) | Aryl substituted propanolamine derivatives, manufacturing methods, drug substances, their use. | |
ATE307591T1 (en) | PREPARATIONS CONTAINING A STEROID HORMONE AND A STABILIZING AGENT IN NON-CRYSTALLINE FORM | |
WO1998058629A3 (en) | Preparation of pharmaceutical compositions | |
MY144897A (en) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
AP1849A (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
MY136686A (en) | Salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide and method of production | |
US20050256080A1 (en) | Method for reducing malodor of chondroitin | |
IL102814A0 (en) | Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them | |
TNSN07013A1 (en) | Anti-histaminic composition | |
MY153713A (en) | A pharmaceutical composition comprising 3, 4-dihydro-3-methyl-4-oxoimidazo [5,1-d]-1,2,3,5-tetrazine-8-carboxylate | |
WO2000054763A3 (en) | Pharmaceutical compositions comprising polymorphic forms of dehydroepiandrosterone | |
YU81101A (en) | Polymorphs of a crystalline azabicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions | |
MXPA04007560A (en) | Oral trimethobenzamide formulations and methods. | |
UA85190C2 (en) | PROCESS FOR THE SYNTHESIS OF PURE D-(17α)-13-ETHYL-17-HYDROXY-18,19-DINORPREGN-4-ENE-20-YNE-3-ONE-3E- AND -3Z-OXIME ISOMERS AND THE MIXTURE OF ISOMERS, AND USE OF THOSE ISOMERS | |
AU2002339199A1 (en) | Solvates of 3.beta., 28-diacetoxy-18-oxo-19, 20, 21, 29, 30-pentanorlupan-22-oic acid, processes for their preparation and pharmaceutical compositions thereof | |
TW200511995A (en) | Antifungal composition | |
BR0215680A (en) | Stable oral pharmaceutical composition | |
UA41161A (en) | Composition for treating periodontitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20130624 |